Dermatology
Partner With Us
Advertisement
Conexiant chevron_right Dermatology chevron_right EXOTIC Trial Tests Extended Interval Omalizumab in CSU
From the Journals

EXOTIC Trial Tests Extended-Interval Omalizumab in Urticaria

Should omalizumab 6-week therapy prove non-inferior to 4-week therapy in maintaining disease control, 'this validation may enhance cost-effectiveness and spare patients of unnecessary injections and hospital visits.'

Conexiant
article Full Article subject Summary summarize Notecard
  1. The EXOTIC trial will examine extending omalizumab dosing from 4 to 6 weeks for chronic spontaneous urticaria patients.
  2. The trial aims to assess the impact on disease control and cost-effectiveness.
  3. Eleven of 39 patients have been enrolled, with recruitment targeted for completion by August 2025.
  4. The primary endpoint will be the difference in urticaria control test scores at week 36, with secondary outcomes including quality-of-life measures and disease control proportion.
  5. Forty patients (20 per arm) will be enrolled to allow for a 20% dropout rate. 

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.